[Receptor mapping in living human beings by means of positron emission tomography].
PET can map neurotransmitter synthesis, storage, release, binding to receptors, and re-uptake in the brain with tracer concentrations in the picomolar or nanomolar range. Tracers are analogues of naturally occurring precursors or ligands, or are drugs, which bind with varying degrees of specificity to receptor subtypes in the brain. Tracers have been synthesised for many transmitter systems, but dopaminergic and serotonergic neurotransmissions are the main foci of current efforts to selectively trace synthesis, storage, re-uptake, or post-synaptic binding of neurotransmitters. Common measures of the tracer uptake and binding include precursor clearance (k3), a measure of transmitter synthesis and trapping, and binding potential (pB), a measure of the receptor binding per unit of unbound tracer, and hence a measure of the release of the endogenous transmitter, or the occupancy of a drug. Dopamine tracers are used in diseases of the basal ganglia, whereas serotonin, benzodiazepine, and opiate tracers are used in lesions of the cerebral cortex. PET has revealed loss of dopaminergic terminals and dopamine synthetic capacity in Parkinson's disease, MPTP intoxication, and Lesch-Nyhan's syndrome; release of dopamine after administration of cocaine and amphetamine, and in motor activity and cognition; increased synaptic dopamine and release of dopamine, and the 70-90% neuroleptic occupancy of dopamine receptors in the striatum, in patients with schizophrenia; loss of muscarinic and nicotinergic receptors in Alzheimer's disease, and benzodiazepine and opiate receptors in stroke, epilepsy, and Huntington's chorea; altered opiate receptors in chronic pain and drug abuse; and release of opiates in analgesia; but changes in serotonin synthesis, transport, and binding in affective or psychotic disorders remain elusive.
Gjedde
A
A
Arhus Universitetshospital, Arhus Kommunehospital, PET-centret.
D001480:Basal Ganglia Diseases / Q000000981:diagnostic imaging; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism; D001927:Brain Diseases / Q000000981:diagnostic imaging*; D001931:Brain Mapping / Q000379:methods*; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000378:metabolism; D006801:Humans; D017981:Receptors, Neurotransmitter / Q000378:metabolism / Q000502:physiology*; D014055:Tomography, Emission-Computed / Q000379:methods*
D017981:Receptors, Neurotransmitter